Skip to main content
SpringerLink
Log in

Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study

  • Pharmacoepidemiology and Prescription
  • Published:
European Journal of Clinical Pharmacology Aims and scope Submit manuscript

Abstract

Introduction

Bisphosphonates are used worldwide to treat osteoporosis and, thus, to prevent fractures. Though they have been proven in clinical trials to avoid some fractures, their effectiveness in reducing hip fractures is unclear. The aim of the present study was to explore the relationship between bisphosphonate use and hip fracture trends in Spain.

Methods

For this purpose, an ecologic study spanning 2002 to 2008 was conducted in Spain. Consumption data were obtained from the Spanish Ministry of Health and Social Policy. The number of hip fractures was obtained from hospital discharges; annual hip fracture rates were determined and standardized using the Spanish 2002 population census. A linear regression was performed between fracture rate and use of bisphosphonates; R 2 and Pearson correlation coefficient were calculated.

Results

From 2002 to 2008, dispensed prescriptions of bisphosphonates in Spain increased from 3.28 to 17.66 DDD/1,000 inhabitants per day. In the same period, the crude hip fracture rate increased from 2.85 to 3.02 cases per 1,000 inhabitants older than 50 years; however, when age standardized rates were estimated, the rate declined from 2.85 to 2.79. Analyzed by sex, the standardized rate for men slightly increased from 1.45 to 1.48, while for women the rate significantly dropped from 4.00 to 3.91.

Conclusion

A small effect of bisphosphonates on hip fracture rates can not be ruled out; however, other factors might partially explain this decline. Assuming this medication was the only cause for hip fracture rate reduction, the elevated medication cost to avoid a single hip fracture makes it necessary to explore less expensive interventions.

This is a preview of subscription content, log in via an institution to check access.

Access this article

Log in via an institution

Price excludes VAT (USA)
Tax calculation will be finalised during checkout.

Instant access to the full article PDF.

Institutional subscriptions

Fig. 1
Fig. 2

Similar content being viewed by others

References

  1. Cummings-Vaughn LA, Gammack JK (2011) Falls, osteoporosis, and hip fractures. Med Clin North Am 95:495–506

    Article  PubMed  Google Scholar 

  2. Haentjens P, Magaziner J, Colón-Emeric CS, Vanderschueren D, Milisen K, Velkeniers B, Boonen S (2010) Meta-analysis: excess mortality after hip fracture among older women and men. Ann Intern Med 152:380–390

    PubMed  Google Scholar 

  3. Haleem S, Lutchman L, Mayahi R, Grice JE, Parker MJ (2008) Injury. Mortality following hip fracture: trends and geographical variations over the last 40 years. Injury 39:1157–1163

    Article  PubMed  CAS  Google Scholar 

  4. National Statistics Institute (2012) Population in Spain. http://www.ine.es/

  5. de Felipe R, Cáceres C, Cimas M, Dávila G, Fernández S, Ruiz T (2010) Clinical characteristics of patients under treatment for osteoporosis in a Primary Care Centre. Who do we treat? Aten Primaria 42:559–563

    Article  PubMed  Google Scholar 

  6. Duarte J, Bolge S, Sen S (2007) An evaluation of patients’ preferences for osteoporosis medications and their attributes: the PREFER-International study. Clin Ther 29:488–503

    Article  PubMed  Google Scholar 

  7. Melton LJ 3rd, Kanis JA, Johnell O (2005) Potential impact of osteoporosis treatment on hip fracture trends. J Bone Miner Res 20:895–897

    Article  PubMed  Google Scholar 

  8. Shane E, Burr D, Ebeling PR, Abrahamsen B, Adler RA, Brown TD, Cheung AM, Cosman F, Curtis JR, Dell R, Dempster D, Einhorn TA, Genant HK, Geusens P, Klaushofer K, Koval K, Lane JM, McKiernan F, McKinney R, Ng A, Nieves J, O'Keefe R, Papapoulos S, Sen HT, van der Meulen MC, Weinstein RS, Whyte M, American Society for Bone and Mineral Research (2010) Atypical subtrochanteric and diaphyseal femoral fractures: report of a task force of the American Society for Bone and Mineral Research. J Bone Miner Res 25:2267–2294

    Article  PubMed  Google Scholar 

  9. Morgenstern H (1982) Uses of ecologic analysis in epidemiologic research. Am J Public Health 72:1336–1344

    Article  PubMed  CAS  Google Scholar 

  10. http://www.imi-protect.eu/documents/DUinventory_2011_6_WORD97-2003.pdf.

  11. Lunde PKM, Baksaas I, Halse M, Strommes B, Aeydvin K (1979) The methodology of drug utilization studies. In: Bergman U, Grimsson A, Wahba AHW, Werterholm B (ed) Studies in drug utilization. WHO Regional Office for Europe, Copenhagen, pp 17–28

    Google Scholar 

  12. WHO Collaborating Centre for Drug Statistics Methodology (2007) Complete ATC index. http://www.whocc.no/atcddd/

  13. Ministerio de Sanidad, Servicios Sociales e Igualdad (2012) Portal estadístico. http://pestadistico.msc.es/PEMSC25/ArbolNodos.aspx

  14. http://www.msc.es/biblioPublic/publicaciones/recursos_propios/infMedic/docs/vol34n3SubgrATCppiosActivos.pdf. Accesed 1 April 2012

  15. http://stat.ethz.ch/R-manual/R-patched/library/stats/html/summary.lm.html

  16. http://www.nice.org.uk/. Accesed 1 April 2012

  17. Chesnut CH III, Skag A, Christiansen C, Recker R, Stakkestad JA, Hoiseth A, Felsenberg D, Huss H, Gilbride J, Schimmer RC, Delmas PD, Oral Ibandronate Osteoporosis Vertebral Fracture Trial in North America and Europe (BONE) (2004) Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis. J Bone Miner Res 19:1241–1249

    Article  CAS  Google Scholar 

  18. Black DM, Cummings SR, Karpf DB, Cauley JA, Thompson DE, Nevitt MC, Bauer DC, Genant HK, Haskell WL, Marcus R, Ott SM, Torner JC, Quandt SA, Reiss TF, Ensrud KE (1996) Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Lancet 348:1535–1541

    Article  PubMed  CAS  Google Scholar 

  19. Black DM, Delmas PD, Eastell R, Reid IR, Boonen S, Cauley JA, Cosman F, Lakatos P, Leung PC, Man Z, Mautalen C, Mesenbrink P, Hu H, Caminis J, Tong K, Rosario-Jansen T, Krasnow J, Hue TF, Sellmeyer D, Eriksen EF, Cummings SR, for the HORIZON Pivotal Fracture Trial (2007) Once-yearly zoledronic acid for treatment of osteoporosis. N Engl J Med 356:1809–1822

    Article  PubMed  CAS  Google Scholar 

  20. McClung MR, Geusens P, Miller PD, Zippel H, Bensen WG, Roux C, Adami S, Fogelman I, Diamond T, Eastell R, Meunier PJ, Reginster JY, for the Hip Intervention Program (HIP) Study Group (2001) Effect of risedronate on the risk of hip fracture in elderly women. N Engl J Med 344:333–340

    Article  PubMed  CAS  Google Scholar 

  21. Wells GA, Cranney A, Peterson J, Boucher M, Shea B, Robinson V, Coyle D, Tugwell P (2008) Alendronate for the primary and secondary prevention of osteoporotic fractures in postmenopausal women. Cochrane Database Syst Rev (1):CD001155

  22. Feldstein AC, Weycker D, Nichols GA, Oster G, Rosales G, Boardman DL, Perrin N (2009) Effectiveness of bisphosphonate therapy in a community setting. Bone 44:153–159

    Article  PubMed  CAS  Google Scholar 

  23. Erviti J, Timoner J, Alonso A, Gorricho J, López A, Huerta C, Oliva B, Gil M, De Abajo F (2011) Oral bisphosphonates and hip fracture risk in elderly women. Pharmacoepidemiol Drug Saf 20:S28

    Google Scholar 

  24. Park-Wyllie LY, Mamdani MM, Juurlink DN, Hawker GA, Gunraj N, Austin PC, Whelan DB, Weiler PJ, Laupacis A (2011) Bisphosphonate use and the risk of subtrochanteric or femoral shaft fractures in older women. JAMA 305:783–789

    Article  PubMed  CAS  Google Scholar 

  25. Schilcher J, Michaëlsson K, Aspenberg P (2011) Bisphosphonate use and atypical fractures of the femoral shaft. N Engl J Med 364:1728–1737

    Article  PubMed  CAS  Google Scholar 

  26. Sellmeyer DE (2010) Atypical fractures as a potential complication of long-term bisphosphonate therapy. JAMA 304:480–484

    Article  Google Scholar 

  27. Wang Z, Bhattacharyya T (2011) Trends in incidence of subtrochanteric fragility fractures and bisphosphonate use among the US elderly, 1996–2007. J Bone Miner Res 26:553–560

    Article  PubMed  CAS  Google Scholar 

  28. Fisher A, Martin J, Srikusalanukul W, Davis M (2010) Bisphosphonate use and hip fracture epidemiology: ecologic proof from the contrary. Clin Interv Aging 5:355–62

    Article  PubMed  Google Scholar 

  29. Hernández JL, Olmos JM, Alonso MA, González-Fernández CR, Martínez J, Pajarón M, Llorca J, González-Macías J (2006) Trend in hip fracture epidemiology over a 14-year period in a Spanish population. Osteoporos Int 17:464–470

    Article  PubMed  Google Scholar 

  30. Guilley E, Chevalley T, Herrmann F, Baccino D, Hoffmeyer P, Rapin CH, Rizzoli R (2008) Reversal of the hip fracture secular trend is related to a decrease in the incidence in institution-dwelling elderly women. Osteoporos Int 19:1741–1747

    Article  PubMed  CAS  Google Scholar 

  31. Brauer CA, Coca-Perraillon M, Cutler DM, Rosen AB (2009) Incidence and mortality of hip fractures in the United States. JAMA 302:1573–1579

    Article  PubMed  CAS  Google Scholar 

  32. Abrahamsen B, Vestergaard P (2010) Declining incidence of hip fractures and the extent of use of anti-osteoporotic therapy in Denmark 1997–2006. Osteoporos Int 21:373–830

    Article  PubMed  CAS  Google Scholar 

  33. Barba R, Losa JE, Guijarro C, Zapatero A (2006) Reliability of minimal basic data set in the diagnosis of thromboembolic disease. Med Clin 127:255–257

    Article  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Centro de Estudios sobre la Seguridad de los Medicamentos, Universidad de Valladolid, Valladolid, Spain

    L. H. Martín Arias, C. Treceño, P. García-Ortega, J. Rodríguez-Paredes, A. Escudero, M. Sáinz, I. Salado, V. Velasco & A. Carvajal

  2. Facultad de Medicina, Ramón y Cajal 7, 47005, Valladolid, Spain

    A. Carvajal

Authors
  1. L. H. Martín Arias
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C. Treceño
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. P. García-Ortega
    View author publications

    You can also search for this author in PubMed Google Scholar

  4. J. Rodríguez-Paredes
    View author publications

    You can also search for this author in PubMed Google Scholar

  5. A. Escudero
    View author publications

    You can also search for this author in PubMed Google Scholar

  6. M. Sáinz
    View author publications

    You can also search for this author in PubMed Google Scholar

  7. I. Salado
    View author publications

    You can also search for this author in PubMed Google Scholar

  8. V. Velasco
    View author publications

    You can also search for this author in PubMed Google Scholar

  9. A. Carvajal
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to A. Carvajal.

Rights and permissions

Reprints and permissions

About this article

Cite this article

Arias, L.H.M., Treceño, C., García-Ortega, P. et al. Hip fracture rates and bisphosphonate consumption in Spain. An ecologic study. Eur J Clin Pharmacol 69, 559–564 (2013). https://doi.org/10.1007/s00228-012-1337-z

Download citation

  • Received:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1007/s00228-012-1337-z

Keywords

Search

Navigation